SCOTTS INTERNATIONAL

Biopsy Devices Market by Product (Core needle biopsy (Automatic, Disposable), Technology (Ultrasound,stereotactic), Application (Oncology, Gastroenterology, Bone & Bone marrow biopsy), End User (Diagnostic imaging centres) - Global Forecast to 2030

Market Report | 2025-03-03 | 504 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User $4950.00
- Multi User $6650.00
- Corporate License $8150.00
- Enterprise Site License $10000.00

Report description:

The global biopsy device market is projected to reach USD 11.01 billion by 2030 from USD 7.27 billion in 2024, at a CAGR of 7.2% during the forecast period."

One of the biggest drivers is the growing incidence of cancer, especially breast, lung, and prostate cancers, which need precise and early diagnostic tests. The World Health Organization states that cancer cases are likely to increase substantially by 2030. Therefore, there would be an increasing demand for biopsy devices. Also, the growing demand for less invasive procedures is driving market growth further. The newer biopsy methods like vacuum-assisted and liquid biopsies are more accurate, have lower recovery times, and cause lower patient discomfort Furthermore, advances in technology, such as robotic-assisted biopsy machines, AI-based diagnostic systems, and image-guided biopsy procedures, improve accuracy and efficiency, driving market growth further. Moreover, rising government programs for cancer screening, combined with rising healthcare spending, especially in developing nations, drive the market forward. Nonetheless, the high prices of sophisticated biopsy devices and strict regulatory environments can serve as constraints.

"The needle-based biopsy instrument segment to grow the fastest during the forecast period."

Based on the product, the biopsy device market is divided into Needle-based biopsy instrument, Visualization device, Brush biopsy instrument, Biopsy accessory and Robotic biopsy device. Among these, in 2023, Needle-based biopsy instrument segment account for the highest growing segment of 7.8% in biopsy device market. This is due to rising preference for the utilization of minimally invasive diagnostic interventions. The Needle biopsy devices such as core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB) devices provide a less painful and less invasive alternative to surgical biopsies.

This lowers patient pain, recovery time, and procedural expenses. Moreover, the growing focus on early disease detection and precision medicine has also driven demand for needle biopsies, as they yield very accurate tissue samples with few complications. Further, the increasing trend towards ambulatory and outpatient facilities for biopsies has also increased the market, as needle biopsies are quick and require little infrastructure. However, the risks of bleeding, infection, and sampling errors pose challenges to the growth of this market.

"The gastroenterology segment accounts for the second largest market share in biopsy device market."

Based on application, the biopsy device market is segmented into oncology, Gastroenterology, Bone & Bone marrow biopsy and other applications. The gastroenterology segment accounts for the second largest market share in biopsy device market. This can be attributed to the growing cased of gastrointestinal (GI) diseases and technological advancements in endoscopic biopsy methods. Moreover, the GI disorders such as Colorectal cancer, gastric cancer, inflammatory bowel disease (IBD), celiac disease, and gastrointestinal infections need biopsy procedures for proper diagnosis. Further, the increasing incidence of colorectal cancer, one of the most recurrently diagnosed cancers globally, makes a major contribution to the need for GI biopsy devices. Furthermore, the growing use of image-guided biopsy methods, namely endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and fine-needle biopsy (EUS-FNB), improves diagnostic accuracy in deep-seated GI tumors, contributing to market growth. Moreover, rise in geriatric population suffering from GI disorders and advancements in healthcare infrastructure on a worldwide level favour market growth.

"Asia Pacific accounted for the fastest growing of the biopsy device market by region."

The global biopsy device market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for the biopsy device and is estimated to grow at the highest CAGR during the forecast period. The increasing incidence of cancer, coupled by demographic changes and lifestyle factors, has increased the need for early diagnosis, driving the use of biopsy procedures. Development of healthcare infrastructure, especially in nations such as China, India, and Japan, has increased access to sophisticated diagnostic technologies. Further, government initiatives and rising healthcare expenditures have also aided cancer screening programs, stimulating market growth. Moreover, the growing medical tourism industry in the region, specifically in countries with low-cost yet high-quality biopsy services, has also increased the growth in demand.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-45%, Tier 2-30%, and Tier 3- 25%
- By Designation: C-level-35%, Director-level-25% and Others-40%
- By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America- 10%, and Middle east and Africa-5%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the biopsy device market are BD (US), Devicor medical products, Inc (US), Medtronic (Ireland), Cardinal Health (US), B.Braun SE (Germany), Hologic,Inc (US), Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Corporation (Japan), Stryker (US), Teleflex Incorporated (US), CONMED Corporation (US), Merit Medical Systems (US), Johnson & Johnson Services,Inc. (US), Cook Group (US), MicroPort Scientific Corporation (China), Argon Medical Devices (US), INRAD, Inc (US), Summit Medical LLC (US), TransMed7, LLC (US), Dr. Japan Co., Ltd. (Japan), IZI Medical Products (US), Planmed Oy (Finland), Advin Health Care (India), Trivitron Healthcare (India).

Research Coverage

This report studies the biopsy device market based on product, type, technology, application end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
- Analysis of Key divers (Rising prevalence of cancer), restraints (Increasing product recalls), Challenge (Technological advancements), opportunity (Underdeveloped healthcare infrastructure in emerging economies)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the bbiopsy device market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the biopsy device market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the biopsy devices market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents:

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 STUDY SCOPE 43
1.3.1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD 43
1.3.2 INCLUSIONS & EXCLUSIONS 44
1.4 YEARS CONSIDERED 45
1.5 CURRENCY CONSIDERED 45
1.6 STAKEHOLDERS 46
1.7 SUMMARY OF CHANGES 46
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH DATA 47
2.1.1 SECONDARY DATA 48
2.1.1.1 Key data from secondary sources 49
2.1.2 PRIMARY DATA 49
2.1.2.1 Key data from primary sources 51
2.1.2.2 Key industry insights 51
2.2 MARKET SIZE ESTIMATION 52
2.3 ASSESSMENT OF MARKET SEGMENTS 56
2.4 ASSESSMENT OF GEOGRAPHIC SEGMENTS 56
2.5 MARKET BREAKDOWN & DATA TRIANGULATION 56
2.6 RESEARCH ASSUMPTIONS 57
2.7 RESEARCH LIMITATIONS 58
2.7.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7.2 SCOPE-RELATED LIMITATIONS 58
2.8 RISK ASSESSMENT 58
3 EXECUTIVE SUMMARY 59

4	PREMIUM INSIGHTS	64
4.1	OPPORTUNITIES FOR PLAYERS IN BIOPSY DEVICES MARKET	64
4.2	NORTH AMERICA: BIOPSY DEVICES MARKET, BY END USER	65
4.3	BIOPSY DEVICES MARKET: GEOGRAPHIC SNAPSHOT	66
4.4	BIOPSY DEVICES MARKET: GEOGRAPHIC MIX	67
4.5	BIOPSY DEVICES MARKET: DEVELOPING VS. DEVELOPED MARKETS,
2024 VS. 2030 (USD MILLION)	67
?
5	MARKET OVERVIEW	68
5.1	INTRODUCTION	68
5.2	MARKET DYNAMICS	68
5.2.1	DRIVERS	69
5.2.1.1	Rising prevalence of cancer	69
5.2.1.2	Increasing preference for minimally invasive surgeries	69
5.2.1.3	Initiatives undertaken by governments and global health organizations	69
5.2.1.4	Increased number of hospitals and diagnostic centers	70
5.2.1.5	Improved reimbursement policies	70
5.2.2	RESTRAINTS	71
5.2.2.1	Increasing product recalls	71
5.2.2.2	High risk of infections	71
5.2.3	OPPORTUNITIES	71
5.2.3.1	Technological advancements	71
5.2.3.2	Growing investments in emerging economies	72
5.2.4	CHALLENGES	72
5.2.4.1	Underdeveloped healthcare infrastructure in emerging economies	72
5.3	INDUSTRY TRENDS	72
5.3.1	MINIMALLY INVASIVE PROCEDURES	73
5.3.2	ROBOTIC-ASSISTED BIOPSY DEVICES	73
5.3.3	LIQUID BIOPSY TECHNOLOGY	74
5.4	TECHNOLOGY ANALYSIS	74
5.4.1	KEY TECHNOLOGIES	74
5.4.1.1	Robotic-assisted biopsy devices	74
5.4.1.2	Optical biopsy technologies	75
5.4.1.3	Minimally invasive biopsy devices	75
5.4.2	COMPLEMENTARY TECHNOLOGIES	75
5.4.2.1	Imaging technologies	75
5.4.2.2	Tissue analysis technologies	76
5.4.2.3	Artificial intelligence	76
5.4.3	ADJACENT TECHNOLOGIES	77
5.4.3.1	Digital pathology and AI integration	77
5.4.3.2	Precision medicine tools	77
5.4.3.3	Advanced needle and probe technologies	77
5.5	PORTER'S FIVE FORCES ANALYSIS	78
5.5.1	THREAT FROM NEW ENTRANTS	78
5.5.2	BARGAINING POWER OF SUPPLIERS	78
5.5.3	BARGAINING POWER OF BUYERS	79
5.5.4	THREAT FROM SUBSTITUTES	79

5.5.5 INTENSITY OF COMPETITIVE RIVALRY 79
?
5.6 REGULATORY LANDSCAPE 80
5.6.1 REGULATIONS, BY REGION 80
5.6.1.1 North America 80
5.6.1.1.1 US 80
5.6.1.1.2 Canada 80
5.6.1.2 Europe 81
5.6.1.3 Asia Pacific 81
5.6.1.4 Latin America 81
5.6.1.5 Middle East & Africa 82
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.7 PATENT ANALYSIS 85
5.7.1 PATENT PUBLICATION TRENDS IN BIOPSY DEVICES MARKET 85
5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 85
5.8 TRADE ANALYSIS 88
5.9 PRICING ANALYSIS 89
5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY KEY PRODUCT 89
5.9.2 AVERAGE SELLING PRICE TREND OF BIOPSY DEVICES, BY REGION 90
5.10 KEY CONFERENCES & EVENTS 90
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 91
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
5.11.2 BUYING CRITERIA 92
5.12 BIOPSY DEVICES MARKET: UNMET NEEDS/EXPECTATIONS OF END USERS 93
5.13 ECOSYSTEM ANALYSIS 94
5.14 CASE STUDY ANALYSIS 95
5.14.1 CASE STUDY 1: DEVICELAB COLLABORATED WITH CLINICAL EXPERTS TO IDENTIFY LIMITATIONS OF EXISTING BREAST BIOPSY PROCEDURES 95
5.14.2 CASE STUDY 2: RESEARCHERS AT UNIVERSITY OF TWENTE DESIGNED ROBOTIC SETUP AND SOFTWARE ARCHITECTURE TO ASSIST RADIOLOGISTS IN TARGETING MRI-DETECTED SUSPICIOUS TUMORS 96
5.14.3 CASE STUDY 3: RESEARCH TEAM DESIGNED FLEXIBLE ROBOTIC SYSTEM FOR BIOPSY SAMPLING APPLIED TO HUMAN CORPSES PLACED INSIDE PROTECTIVE BODY BAGS 96
5.15 SUPPLY CHAIN ANALYSIS 97
5.16 ADJACENT MARKET ANALYSIS 99
5.16.1 BREAST BIOPSY DEVICES MARKET 99
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 100
5.18 INVESTMENT & FUNDING SCENARIO 101
5.19 IMPACT OF AI ON BIOPSY DEVICES MARKET 101
?
6 BIOPSY DEVICES MARKET, BY PRODUCT 103
6.1 INTRODUCTION 104
6.2 NEEDLE-BASED BIOPSY INSTRUMENT 105
6.2.1 CORE NEEDLE BIOPSY 107
6.2.1.1 Core needle biopsy device 110
6.2.1.1.1 Semi-automatic 114
6.2.1.1.1.1 Need for balance of user control and automated functionality in procedures to drive market 114
6.2.1.1.2 Automatic 116

6.2.1.1.2.1 Demand for efficiency and accuracy in biopsy procedures to boost growth 116
6.2.1.2 Core needle biopsy needle 118
6.2.1.2.1 Disposable 121
6.2.1.2.1.1 Need for infection control and safety concerns to boost growth 121
6.2.1.2.2 Reusable 123
6.2.1.2.2.1 Cost-effectiveness of reusable core biopsy needles to drive market 123
6.2.2 FINE NEEDLE ASPIRATION BIOPSY 125
6.2.2.1 Innovations in needle design, including thinner profiles and improved tip configurations, to drive market 125
6.2.3 VACUUM-ASSISTED BIOPSY 128
6.2.3.1 Increasing need for early and accurate cancer detection to drive market 128
6.3 VISUALIZATION DEVICE/SYSTEM 131
6.3.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC CONDITIONS
TO DRIVE DEMAND FOR VISUALIZATION DEVICE 131
6.4 BRUSH BIOPSY INSTRUMENT 133
6.4.1 PREFERENCE FOR MINIMALLY INVASIVE BIOPSY PROCEDURES
TO BOOST MARKET 133
6.5 BIOPSY ACCESSORY 135
6.5.1 BIOPSY FORECEP 138
6.5.1.1 General biopsy forcep 141
6.5.1.1.1 Demand for minimally invasive procedures and precise diagnostics to surge growth 141
6.5.1.2 Hot biopsy forecep 143
6.5.1.2.1 Unique ability of hot biopsy forecep to cut and coagulate tissue to support growth 143
6.5.2 TISSUE MARKER 145
6.5.2.1 Rising cases of breast cancer to boost market growth 145
6.5.3 LOCALIZATION WIRE 147
6.5.3.1 Ability of localization wire to detect precise target locations to drive growth 147
6.5.4 OTHER ACCESSORIES 150
6.6 ROBOTIC BIOPSY DEVICE 151
6.6.1 RAPID DEVELOPMENT OF ROBOTIC BIOPSY DEVICES TO BOOST GROWTH 151
7 BIOPSY DEVICES MARKET, BY TECHNOLOGY 154
7.1 INTRODUCTION 155
7.2 ULTRASOUND-GUIDED BIOPSY 155
7.2.1 ULTRASOUND GUIDANCE ENHANCES SAFETY, MINIMIZES COMPLICATIONS, AND IMPROVES DIAGNOSTIC ACCURACY 155
7.3 STEREOTACTIC-GUIDED BIOPSY 157
7.3.1 NEED FOR EFFICIENT AND ACCURATE BIOPSY PROCEDURES
TO SUPPORT MARKET GROWTH 157
7.4 OTHER TECHNOLOGIES 159
8 BIOPSY DEVICES MARKET, BY APPLICATION 162
8.1 INTRODUCTION 163
8.2 ONCOLOGY 164
8.2.1 BREAST CANCER 166
8.2.1.1 Increasing demand for early and accurate diagnosis to boost growth 166
8.2.2 SOFT TISSUE CANCER 168
8.2.2.1 Advancements in diagnostics and growing emphasis on cancer therapeutics to drive market 168
8.3 GASTROENTEROLOGY 170
8.3.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE MARKET 170
8.4 BONE & BONE MARROW BIOPSY 172

8.4.1 RISING EMPHASIS ON BONE MARROW BIOPSIES
TO SUPPORT MARKET GROWTH 172
8.5 OTHER APPLICATIONS 175
9 BIOPSY DEVICES MARKET, BY END USER 177
9.1 INTRODUCTION 178
9.2 HOSPITALS & BREAST CARE CENTERS 179
9.2.1 DEMAND FOR STATE-OF-THE-ART BIOPSY FACILITIES TO DRIVE MARKET 179
9.3 DIAGNOSTIC IMAGING CENTERS 182
9.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS
TO SUPPORT MARKET GROWTH 182
9.4 AMBULATORY SURGICAL CENTERS 184
9.4.1 GROWING FOCUS ON AMBULATORY CARE TO DRIVE MARKET 184
9.5 OTHER END USERS 187
10 BIOPSY DEVICES MARKET, BY REGION 189
10.1 INTRODUCTION 190
10.2 NORTH AMERICA 193
10.2.1 MACROECONOMIC OUTLOOK 193
10.2.2 US 203
10.2.2.1 Growth in elderly population to drive market 203
10.2.3 CANADA 212
10.2.3.1 Rising government investments to drive growth 212
10.3 EUROPE 220
10.3.1 MACROECONOMIC OUTLOOK 220
10.3.2 GERMANY 229
10.3.2.1 Increasing prevalence of chronic diseases to propel market 229
10.3.3 UK 237
10.3.3.1 Initiatives by government to support market growth 237
10.3.4 FRANCE 245
10.3.4.1 Rising number of diagnostic imaging centers to drive market 245
10.3.5 ITALY 254
10.3.5.1 Availability of reimbursement coverage to support market growth 254
10.3.6 SPAIN 262
10.3.6.1 Increasing focus on cancer research to propel market 262
10.3.7 REST OF EUROPE 270
10.4 ASIA PACIFIC 278
10.4.1 MACROECONOMIC OUTLOOK 278
10.4.2 CHINA 289
10.4.2.1 Rapidly growing geriatric population to propel market 289
10.4.3 JAPAN 297
10.4.3.1 High adoption of advanced technologies to support market growth 297
10.4.4 INDIA 306
10.4.4.1 Rising prevalence of chronic diseases to drive market 306
10.4.5 AUSTRALIA 314
10.4.5.1 Increasing investments in research to provide opportunities for market growth 314
10.4.6 SOUTH KOREA 322
10.4.6.1 Presence of well-developed healthcare systems to propel market 322
10.4.7 REST OF ASIA PACIFIC 330

10.5	LATIN AMERICA	338
10.5.1	MACROECONOMIC OUTLOOK	339
10.5.2	BRAZIL	347
10.5.2.1	Favourable demographic conditions to drive market	347
10.5.3	MEXICO	356
10.5.3.1	Increased medical tourism and better government healthcare initiatives to drive market	356
10.5.4	REST OF LATIN AMERICA	364
10.6	MIDDLE EAST & AFRICA	372
10.6.1	MACROECONOMIC OUTLOOK	372
10.6.2	GCC COUNTRIES	381
10.6.2.1	Expansion of healthcare providers to drive growth	381
10.6.3	REST OF MIDDLE EAST & AFRICA	389
11	COMPETITIVE LANDSCAPE	397
11.1	OVERVIEW	397
11.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	397
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPSY DEVICES MARKET	397
11.3	REVENUE ANALYSIS	399
11.4	MARKET SHARE ANALYSIS	399
11.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	402
11.5.1	STARS	402
11.5.2	EMERGING LEADERS	402
11.5.3	PERVASIVE PLAYERS	402
11.5.4	PARTICIPANTS	403
11.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	404
11.5.5.1	Company footprint	404
11.5.5.2	Region footprint	405
11.5.5.3	Product footprint	406
11.5.5.4	Technology footprint	407
11.5.5.5	Application footprint	408
11.5.5.6	End user footprint	409
11.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	410
11.6.1	PROGRESSIVE COMPANIES	410
11.6.2	RESPONSIVE COMPANIES	410
11.6.3	DYNAMIC COMPANIES	410
11.6.4	STARTING BLOCKS	410
11.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	411
11.7	COMPANY VALUATION & FINANCIAL METRICS	413
11.7.1	COMPANY VALUATION	413
11.7.2	FINANCIAL METRICS	413
11.8	BRAND/PRODUCT COMPARISON	414
11.9	COMPETITIVE SCENARIO	415
11.9.1	PRODUCT LAUNCHES & APPROVALS	415
11.9.2	DEALS	415
11.9.3	EXPANSIONS	416
12	COMPANY PROFILES	417
12.1	KEY PLAYERS	417
12.1.1	BD (BECTON, DICKINSON AND COMPANY)	417

12.1.1.1 Business overview 417
12.1.1.2 Products offered 419
12.1.1.3 Recent developments 427
12.1.1.3.1 Deals 427
12.1.1.4 MnM view 428
12.1.1.4.1 Key strengths 428
12.1.1.4.2 Strategic choices 428
12.1.1.4.3 Weaknesses & competitive threats 428
12.1.2 DEVICOR MEDICAL PRODUCTS, INC 429
12.1.2.1 Business overview 429
12.1.2.2 Products offered 430
12.1.2.3 Recent developments 433
12.1.2.3.1 Product launches & approvals 433
12.1.2.4 MnM view 433
12.1.2.4.1 Key strengths 433
12.1.2.4.2 Strategic choices 433
12.1.2.4.3 Weaknesses & competitive threats 434
12.1.3 MEDTRONIC 435
12.1.3.1 Business overview 435
12.1.3.2 Products offered 437
12.1.3.3 MnM view 438
12.1.3.3.1 Key strengths 438
12.1.3.3.2 Strategic choices 439
12.1.3.3.3 Weaknesses & competitive threats 439
12.1.4 CARDINAL HEALTH 440
12.1.4.1 Business overview 440
12.1.4.2 Products offered 442
12.1.4.3 MnM view 442
12.1.4.3.1 Key strengths 442
12.1.4.3.2 Strategic choices 442
12.1.4.3.3 Weaknesses & competitive threats 443
12.1.5 HOLOGIC, INC. 444
12.1.5.1 Business overview 444
12.1.5.2 Products offered 446
12.1.5.3 Recent developments 448
12.1.5.3.1 Deals 448
12.1.5.3.2 Other developments 449
12.1.5.4 MnM view 449
12.1.5.4.1 Key strengths 449
12.1.5.4.2 Strategic choices 449
12.1.5.4.3 Weaknesses & competitive threats 449
12.1.6 B. BRAUN SE 450
12.1.6.1 Business overview 450
12.1.6.2 Products offered 452
12.1.7 OLYMPUS CORPORATION 454
12.1.7.1 Business overview 454
12.1.7.2 Products offered 456

12.1.7.3 Recent developments 457
12.1.7.3.1 Deals 457
12.1.8 BOSTON SCIENTIFIC CORPORATION 458
12.1.8.1 Business overview 458
12.1.8.2 Products offered 460
12.1.9 FUJIFILM CORPORATION 462
12.1.9.1 Business overview 462
12.1.9.2 Products offered 464
12.1.10 STRYKER 465
12.1.10.1 Business overview 465
12.1.10.2 Products offered 466
12.1.11 TELEFLEX INCORPORATED 467
12.1.11.1 Business overview 467
12.1.11.2 Products offered 469
12.1.12 CONMED CORPORATION 470
12.1.12.1 Business overview 470
12.1.12.2 Products offered 472
12.1.13 MERIT MEDICAL SYSTEMS 474
12.1.13.1 Business overview 474
12.1.13.2 Products offered 476
12.1.14 JOHNSON & JOHNSON SERVICES, INC. 479
12.1.14.1 Business overview 479
12.1.14.2 Products offered 480
12.1.15 COOK GROUP 481
12.1.15.1 Business overview 481
12.1.15.2 Products offered 481
12.1.15.3 Recent developments 484
12.1.15.3.1 Product launches & approvals 484
12.2 OTHER PLAYERS 485
12.2.1 MICROPORT SCIENTIFIC CORPORATION 485
12.2.2 ARGON MEDICAL DEVICES 486
12.2.3 INRAD, INC. 487
12.2.4 SUMMIT MEDICAL LLC 488
12.2.5 TRANSMED7, LLC 489
12.2.6 DR. JAPAN CO., LTD. 490
12.2.7 IZI MEDICAL PRODUCTS 491
12.2.8 PLANMED OY 492
12.2.9 ADVIN HEALTH CARE 493
12.2.10 TRIVITRON HEALTHCARE 494
?
13 APPENDIX 495
13.1 DISCUSSION GUIDE 495
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 500
13.3 CUSTOMIZATION OPTIONS 502
13.4 RELATED REPORTS 502
13.5 AUTHOR DETAILS 503

Biopsy Devices Market by Product (Core needle biopsy (Automatic, Disposable), Technology (Ultrasound,stereotactic), Application (Oncology, Gastroenterology, Bone & Bone marrow biopsy), End User (Diagnostic imaging centres) - Global Forecast to 2030

Market Report | 2025-03-03 | 504 pages | MarketsandMarkets

To place an Order with Scotts International:
- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	$4950.00
	Multi User	$6650.00
	Corporate License	$8150.00
	Enterprise Site License	$10000.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	

Zip Code*		Country*	
		Date	2026-06-09
		Signature	